By Denise Dador
Tuesday, May 02, 2017 11:02PM
LOS ANGELES (KABC) -- A group in Southern California said many people suffering from acid reflux are unaware it can cause cancer, and those who do know may believe over-the-counter heartburn medications reduce their risk of developing cancer.
But the Esophageal Cancer Action Network said the medications don't protect against cancer or Barr...
Read More
HCSC Establishes Positive Coverage Policy for Torax Medical’s LINX Procedure to Treat Gastroesophageal Reflux Disease
09:00 ET from Torax Medical, Inc.
ST. PAUL, Minn., April 7, 2016 /PRNewswire/ -- Torax Medical, Inc., a leader in devices to treat sphincter-related diseases, including gastroesophageal reflux disease (GERD), announced today that Health Care Service Corporation (HCSC), the 4thlargest commercial health insurer in the U.S., has issued a medical coverage policy for the LINX® Reflux Manag...
Read More
Tony D.
As a kid growing up, starting at the age of 9 in 1980, I started to get this burning sensation in my chest and throat. I thought it was normal. I remember telling my Dad about it and he gave me Rolaids. Interestingly, he seemed always to have Rolaids on him. Thinking back, he probably suffered from recurring heartburn as well.
I would get heartburn at least twice a week, every week and this con...
Read More
American Medical Association Creates New Category 1 Code for Torax Medical’s LINX Procedure to Treat Gastroesophageal Reflux Disease
November 18, 2015 05:00 AM Eastern Standard Time
ST. PAUL, Minn.--(BUSINESS WIRE)--Torax Medical, Inc., a leader in therapeutic interventions for sphincter-related diseases, including gastroesophageal reflux disease (GERD), announced today the American Medical Association (AMA) has created a new Category 1 Current Procedural Terminology (CPT®) Code for esophageal sphincter augmentation using ...
Read More
Study: Long-Term Outcomes of Patients Receiving a Magnetic Sphincter Augmentation Device for Gastroesophageal Reflux
Abstract
Background & Aims
Based on results from year 2 of a 5-year trial, in 2012 the US Food and Drug Administration approved the use of a magnetic device to augment lower esophageal sphincter function in patients with gastroesophageal reflux disease (GERD). We report the final results of 5 years of follow-up evaluation of patients who received this device.
Methods
We performed a prosp...
Read More
New 5-Year Results of a Landmark Study Confirm LINX Procedure as a Beneficial Treatment for Gastro-esophageal Reflux Disease
Study authors conclude LINX should be a first line therapy option for GERD sufferers
PR Newswire, St. Paul, Minn. (September 14, 2015)
Torax Medical announced completion of a landmark study confirming the long-term results of the LINX® Reflux Management System in controlling reflux-related symptoms and eliminating dependence on acid suppression medications called proton pump inhibitors (PPIs). F...
Read More
New Study Demonstrates LINX® Safety and Efficacy Rivals Laparoscopic Nissen Fundoplication
Study authors conclude LINX is as effective as Nissen in controlling reflux with less side effects
July 27, 2015 05:00 AM Eastern Daylight Time
ST. PAUL, Minn.--(BUSINESS WIRE)--Torax Medical, Inc. announced today the release of new data from the University of Southern California, Keck Medical Center, a leading institution in the diagnosis and treatment of gastro-esophageal reflux disease (GERD)...
Read More
Nissen Fundoplication
In this video, Dr. Wilson Tsai describes and compares the normal physiology of the esophagus, chest and abdominal cavities to one that has a hiatal hernia causing GERD. He then describes one possible treatment for this type of structural or mechanical issue.
Read More
Torax Medical Announces FDA Approval of a New LINX® Device Compatible with 1.5 Tesla Magnetic Resonance Imaging (MRI) Systems
New LINX Device expands patients’ diagnostic imaging options after treatment
June 23, 2015 05:00 AM Eastern Daylight Time
ST. PAUL, Minn.--(BUSINESS WIRE)--Torax Medical, Inc. is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved a next generation LINX® Reflux Management System that is MR conditional in magnetic resonance imaging (MRI) systems up to 1.5 Tesla (...
Read More
Final Results of a Landmark 5-Year Clinical Trial for LINX®, a Revolutionary Solution for GERD, to Be Presented at the Upcoming Digestive Diseases Week Meeting
May 12, 2015 05:30 AM Eastern Daylight Time
ST. PAUL, Minn.--(BUSINESS WIRE)--Torax Medical is pleased to announce the 5-year results from a landmark clinical trial of LINX®, a revolutionary solution for GERD, will be presented at the upcoming Digestive Diseases Week (DDW) being held in Washington, DC from May 16th - 20th.
Dr. Robert Ganz, MD, FASGE, Chief of Gastroenterology, Abbott-North...
Read More